News |  Contact |  Sitemap |  Disclaimer | 
About us  |   Business Development  |   Territories  |   Partners  |  
Bosnia and Herzegovina

Still regarded as a transition economy, Bosnia and Herzegovina (BiH) sees the long-term goal of EU membership as a driver to further economic growth and development. Due to Bosnia and Herzegovina's strict currency board regime, which links the Konvertibilna Marka (BAM or KM) to the Euro, inflation has remained relatively low and, as a result, the BAM is one of the most stable currencies in Southeast Europe.

 

More than 3% of expected GDP growth in 2016 comparing 2015 shows a trend of further economic recovery which was slowed down due to catastrophic floods which hit BiH in 2014. In July 2015, the Council of Ministers of Bosnia and Herzegovina, Government of Republika Srpska, and Government of the Federation of Bosnia and Herzegovina adopted a joint program of structural reforms – known as the Reform Agenda. This Reform Agenda presents a rare window of opportunity for structural reform in BiH, underpinned by a broad national consensus on the country’s critical challenges and priorities and the sustained support of key development partners. Strengthening public finance, improving the business environment in the country, and advancing the institutional and labor market are among the areas where BiH could make notable progress in fostering job creation and growth in the medium term.

 

The Agency for Medicinal Products and Medical Devices of Bosnia and Herzegovina (ALMBIH) has published its annual report on the value of the imported drugs and domestically produced medicines sold in the country's market. As the ALMBIH figures show, the value of the pharmaceutical market of Bosnia and Herzegovina (BiH) in 2014 was BAM 531.441 million, which constitute increase compared with 2013 of 0,8% year on year (y/y) and recovery after 2013 when market declined for 4,4% compared to 2012. On the other hand IMS reported 7,5% growth of registered medicines (OTC and RX) in first quartal of 2015 comparing to 2014  and about market size of 270 mio EUR. Volume growth is significant driver of market growth, while negative price changes offset it.

 

 

Key facts and figures:

 

Area:   51'197 km2
Capital:   Sarajevo
Population:   3,81 million (2015)
Currency:   Convertible Mark (BAM)
     
Volume of pharmaceutical market:   EUR 287 million (2015)       
Of which imported drugs:   81%
No. of hospitals:   30
No. of physicians:   8'576
No. of pharmacies:   1'100
     
Our subsidiary:  

Ewopharma d.o.o Sarajevo
Rajlovačka cesta 23
BA-71000 Sarajevo
Phone: +387 33 592 140

E-Mail: info@ewopharma.ba
     
Employees:  
Administration 1
Sales and Marketing 4